Treatment of Her2-positive or Her2-negative tumor cells by EDC-Herceptin conjugate.

<p>(<b>a</b>) Comparison of cell survival rates between wild-type Herceptin and EDC-Herceptin conjugate treatments in Her2-positive (OS187, CCH.OS.D, and SKBR3) and Her2-negative (Col and MDA-MB-468) cell lines. MTT assay was used after cells were treated with the described antibody at low concentration (20 µg/mL) or high concentration (80 µg/mL) for 72 h. (<b>b</b>) Her2 expression analysis in tested cell lines using flow cytometry as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0023270#pone-0023270-g001" target="_blank">Figure 1</a>. *, <i>P</i><0.05; **, <i>P</i><0.01; ***, <i>P</i><0.001.